# Cetuximab Standard or Dose Escalation in First Line Colorectal Cancer

> **NCT01251536** · PHASE2 · COMPLETED · sponsor: **Universitaire Ziekenhuizen KU Leuven** · enrollment: 108 (actual)

## Conditions studied

- Colorectal Cancer

## Interventions

- **DRUG:** Dose escalation of cetuximab
- **DRUG:** Standard first line treatment with cetuximab + Folfiri

## Key facts

- **NCT ID:** NCT01251536
- **Lead sponsor:** Universitaire Ziekenhuizen KU Leuven
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-12
- **Primary completion:** 2016-06
- **Final completion:** 2019-07
- **Target enrollment:** 108 (ACTUAL)
- **Last updated:** 2019-10-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01251536

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01251536, "Cetuximab Standard or Dose Escalation in First Line Colorectal Cancer". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT01251536. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*